SCHEMBL3174668

SCHEMBL3174668

N#Cc1ncc(Br)c(N(NC(=O)c2cccc(CN3CCC(N4CCOCC4)CC3)c2)C2CCCCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.44
CTSK P43235 3/20 0.44
CTSL P07711 2/20 0.44
CTSB P07858 1/20 0.44
ACVR1 Q04771 4/20 0.38
ACKR3 P25106 3/20 0.38
BMPR1B O00238 1/20 0.38
BMPR1A P36894 1/20 0.38
TGFBR1 P36897 1/20 0.38
ACVRL1 P37023 1/20 0.38
RORC P51449 1/20 0.37
CXCR3 P49682 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
MBTD1 Q05BQ5 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.36
TACR2 P21452 1/20 0.35
TACR3 P29371 1/20 0.35
ADORA2A P29274 1/20 0.35
FAAH O00519 1/20 0.35
MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3176029 0.99 CTSS (0.44) CTSSCTSKCTSLCTSBACVR1
Trifluoroacetic Acid SCHEMBL3166663 0.95 CTSL (0.41) CTSSCTSKCTSLCTSBACVR1
Trifluoroacetic Acid SCHEMBL3165468 0.95 CTSL (0.41) CTSSCTSKCTSLCTSBACVR1
SCHEMBL3159740 0.92 CTSS (0.52) CTSSCTSKCTSLCTSBACKR3
SCHEMBL14142824 0.92 ACVR1 (0.38) CTSSCTSKCTSLCTSBACVR1
SCHEMBL3159702 0.91 CTSS (0.53) CTSSCTSKCTSLCTSBACVR1
SCHEMBL3165237 0.91 CTSS (0.53) CTSSCTSKCTSLCTSBACKR3
SCHEMBL3159657 0.91 CTSL (0.54) CTSSCTSKCTSLCTSBACVR1
Trifluoroacetic Acid SCHEMBL3160111 0.87 CTSS (0.48) CTSSCTSKCTSLCTSBACKR3
Trifluoroacetic Acid SCHEMBL3166874 0.87 CTSL (0.49) CTSSCTSKCTSLCTSBACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US claimed
EP-2030621-A1 Novel substituted pyrimidines as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-03-04 EP claimed
EP-1947091-A1 Pyrimidyl nitrile derivatives as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2008-07-23 EP claimed
EP-1918284-A1 Hydrazinopyrimidines as cysteine protease inhibitors GLAXO GROUP (GB) 2008-05-07 EP claimed
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
EP-2030621-A1 Novel substituted pyrimidines as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-03-04 EP disclosed
EP-1947091-A1 Pyrimidyl nitrile derivatives as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
WO-2008052934-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed
EP-1918284-A1 Hydrazinopyrimidines as cysteine protease inhibitors GLAXO GROUP (GB) 2008-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS SERPINB1, CTRL, PRSS1 CTSS 15/4885CTSK 65/4885CTSL 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.